文献速递消化道肿瘤与早癌消化内镜

一次性结肠镜、乙状结肠镜与多轮邮寄FIT在结直肠癌筛查中的诊断收益比较

Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-08-13

在荷兰30,007名50-74岁无症状人群中比较四轮邮寄FIT、一次性柔性乙状结肠镜和一次性结肠镜筛查。意向筛查分析中FIT组晚期肿瘤累积诊断收益4.5%,高于结肠镜2.2%和乙状结肠镜2.3%;实际筛查分析中结肠镜9.1%和乙状结肠镜7.4%高于FIT 6.1%。

要点

  • 意向筛查分析中FIT组晚期肿瘤诊断收益4.5%,高于结肠镜2.2%和乙状结肠镜2.3%。
  • 实际筛查分析中结肠镜组9.1%、乙状结肠镜组7.4%,均高于FIT组6.1%。
  • FIT组需结肠镜检查的比例13%,低于结肠镜组24%,高于乙状结肠镜组3%。

核心结论

  • 在人群水平上,多轮邮寄FIT相比一次性柔性乙状结肠镜或一次性结肠镜可检出显著更多的晚期肿瘤。
  • 接受多轮FIT筛查者所需的结肠镜检查数量显著更少。

研究设计与样本

  • 荷兰邀请30,007名50-74岁无症状者参加结直肠癌筛查,分配至四轮邮寄FIT组(15,046人)、一次性柔性乙状结肠镜组(8,407人)或一次性结肠镜组(6,600人)。
  • FIT阳性(≥10 μg Hb/g粪便)者转诊结肠镜;乙状结肠镜发现≥10 mm息肉、≥25%绒毛状组织学或高级别异型增生腺瘤、无蒂锯齿状腺瘤、≥3个腺瘤、≥20个增生性息肉或浸润性结直肠癌者转诊结肠镜。
  • 主要结局为各筛查方法检出的晚期肿瘤数(诊断收益);次要结局为检出晚期肿瘤所需结肠镜数和各筛查方法间期结直肠癌数。
  • 间期结直肠癌通过链接荷兰癌症登记处发现;晚期肿瘤定义为结直肠癌、≥10 mm腺瘤、高级别异型增生腺瘤或至少25%绒毛成分腺瘤。

主要发现

  • FIT组累计参与率73%,高于柔性乙状结肠镜组31%(P < .001)和结肠镜组24%(P < .001)。
  • 受邀者中接受结肠镜的比例结肠镜组24%,高于FIT组13%(P < .001)和柔性乙状结肠镜组3%(P < .001)。
  • 意向筛查分析中,FIT组晚期肿瘤累积诊断收益4.5%(95% CI 4.2-4.9),高于结肠镜组2.2%(95% CI 1.8-2.6)和柔性乙状结肠镜组2.3%(95% CI 2.0-2.7)。
  • 实际筛查分析中,结肠镜组晚期肿瘤累积收益9.1%(95% CI 7.7-10.7)和柔性乙状结肠镜组7.4%(95% CI 6.5-8.5),均高于FIT组6.1%(95% CI 5.7-6.6)。
  • 三种筛查策略检出的结直肠癌患者比例相似;随访时间不同(FIT和柔性乙状结肠镜中位8.3年,结肠镜中位5.8年)。

关键数值与推荐

  • FIT阳性阈值:≥10 μg Hb/g粪便。
  • 柔性乙状结肠镜转诊结肠镜标准:≥10 mm息肉;≥25%绒毛状组织学或高级别异型增生腺瘤;无蒂锯齿状腺瘤;≥3个腺瘤;≥20个增生性息肉;或浸润性结直肠癌。
  • 晚期肿瘤定义:结直肠癌、≥10 mm腺瘤、高级别异型增生腺瘤或至少25%绒毛成分腺瘤。

临床怎么用

  • 在人群筛查层面,多轮邮寄FIT可检出更多晚期肿瘤且需结肠镜数量更少。
  • 实际接受筛查者中,一次性结肠镜或柔性乙状结肠镜的晚期肿瘤检出比例高于多轮FIT。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We compared the diagnostic yields of colonoscopy, flexible sigmoidoscopy, and fecal immunochemical tests (FITs) in colorectal cancer (CRC) screening. METHODS: A total of 30,007 asymptomatic persons, 50-74 years old, were invited for CRC screening in the Netherlands. Participants were assigned to groups that received 4 rounds of FIT (mailed to 15,046 participants), once-only flexible sigmoidoscopy (n = 8407), or once-only colonoscopy (n = 6600). Patients with positive results from the FIT (≥10 μg Hb/g feces) were referred for colonoscopy. Patients who underwent flexible sigmoidoscopy were referred for colonoscopy if they had a polyp of ≥10 mm; adenoma with ≥25% villous histology or high-grade dysplasia; sessile serrated adenoma; ≥3 adenomas; ≥20 hyperplastic polyps; or invasive CRC. The primary outcome was number of advanced neoplasia detected (diagnostic yield) by each test. Secondary outcomes were number of colonoscopies needed to detect advanced neoplasia and number of interval CRCs found during each primary screening test. Patients with interval CRCs were found through linkage with Netherlands Cancer Registry. Advanced neoplasia were defined as CRC, adenomas ≥ 10 mm, adenomas with high-grade dysplasia, or adenomas with a villous component of at least 25%. RESULTS: The cumulative participation rate was significantly higher for FIT screening (73%) than for flexible sigmoidoscopy (31%; P < .001) or colonoscopy (24%; P < .001). The percentage of colonoscopies among invitees was higher for colonoscopy (24%) compared to FIT (13%; P < .001) or flexible sigmoidoscopy (3%; P < .001). In the intention to screen analysis, the cumulative diagnostic yield of advanced neoplasia was higher with FIT screening (4.5%; 95% CI 4.2-4.9) than with colonoscopy (2.2%; 95% CI, 1.8-2.6) or flexible sigmoidoscopy (2.3%; 95% CI, 2.0-2.7). In the as-screened analysis, the cumulative yield of advanced neoplasia was higher for endoscopic screening with colonoscopy (9.1%; 95% CI, 7.7-10.7) or flexible sigmoidoscopy (7.4%; 95% CI, 6.5-8.5) than with the FIT (6.1%; 95% CI, 5.7-6.6). All 3 screening strategies detected a similar proportion of patients with CRC. Follow-up times differed for each test (median 8.3 years for FIT and flexible sigmoidoscopy and 5.8 years for colonoscopy). Proportions of patients that developed interval CRC were 0.13% for persons with a negative result from FIT, 0.09% for persons with a negative result from flexible sigmoidoscopy, and 0.01% for persons with a negative result from colonoscopy. CONCLUSIONS: Mailed multiple-round FITs detect significantly more advanced neoplasia, on a population level, compared with once-only flexible sigmoidoscopy or colonoscopy screening. Significantly fewer colonoscopies are required by individuals screened by multiple FITs. Trialregister.nl numbers: first round, NTR1096; second round and additional invitees, NTR1512; fourth round, NTR5874; COCOS trial NTR1829.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Grobbee EJ, van der Vlugt M, van Vuuren AJ, et al. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening. Clin Gastroenterol Hepatol. 2019. PMID: 31419575. doi:10.1016/j.cgh.2019.08.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。